login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Clobazam Study on Ovation Scripts Another Milestone
September 10, 2007 at 9:26 PM
Drug News
LGS, like many catastrophic epilepsies, can be both devastating and overwhelming for patients and their families, and clobazam may offer improved seizure control for patients affected by this condition, said Stephen D. Collins M.D., Ph.D., Chief Scientific Officer and Vice President of Clinical Affairs, Ovation Pharmaceuticals. OVATION remains committed to exploring new treatment options for epilepsy, particularly where current treatment needs are not fully addressed.
The Phase III study is designed to evaluate the safety and efficacy of clobazam in the reduction of atonic seizures at three dose levels in children and adults (ages 2-60 years) with LGS. The company plans to recruit patients with LGS at approximately 60-65 sites. The double-blind, placebo-controlled study will last up to 23 weeks. For more information and study locations, please visit www.clinicaltrials.gov.
|
|
|
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
|
|
- News Quick Links
| News Categories: |
| » | Report: A Lot of Americans Have No Access to Health Care |
| » | Greece Faces Humanitarian Crisis as Health Care Access Declines in EU, Doctors Group Warns |
| » | HCCI Report Says Rising Prices for Care Responsible for Increased Healthcare Costs for Privately Insured Americans |
| » | Treatment in ED is Based on Children's Insurance Status |
| » | US Spends Most on Healthcare Without Providing Superior Care |
| More Insurance News | |
|
